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SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
Isolation and Expression of Antibody 44-VRC13.01, C38-VRC16.01, C38-VRC18.01, and Z258-
VRC27.01 
Antigen-specific memory B cells from donors NIH44, NIHC38 and NIHZ258 were isolated 
with Avi-tagged RSC3 and ∆RSC3 and single-cell sorted on a FACS Aria II as described previously 
(Wu et al., 2010). Kappa and lambda light chain gene and IgG heavy chain gene variable regions 
were amplified using nested PCR, and positive 2nd round PCR products were cherry-picked for 
direct sequencing. Heavy and light chain nucleotide sequences of the variable region were analyzed 
using IMGT\V-Quest (http://www.imgt.org/IMGT_vquest/share/textes/imgtvquest.html). First-round 
PCR products were re-amplified with custom primers containing restriction digest sites followed by 
subcloning, expression and purification as previously described (Wu et al., 2010). Heavy chains 
were reconstituted as IgG1. The antibody names are designated with a “donor-antibody 
lineage.clone” convention and therefore called 44-VRC13.01, C38-VRC16.01, C38-VRC18.01 and 
Z258-VRC27.01. 
 
Neutralization Assays 
Single round of replication Env-pseudoviruses were prepared, titered and used to infect 
TZM-bl target cells as described previously (Montefiori, 2009). Neutralization breadth of VRC13.01, 
VRC16.01, VRC18.01 and VRC27.01 were determined using a previously described panel of 176 
geographically and genetically diverse Env-pseudoviruses representing the major subtypes and 
circulating recombinant forms (Wu et al., 2010). The data were calculated as a reduction in 
luminescence units compared with control wells, and reported as half-maximum inhibitory 
concentration (IC50) in micrograms per milliliter for monoclonal antibodies. 
 
X-Ray Crystallography 
 The gp120-antibody complexes were formed by mixing deglycosylated gp120 with the 
antibody Fab in a 1:2 molar ratio. The complexes were purified by size exclusion chromatography 
(Hiload 26/60 Superdex S200 prep grade; GE Healthcare) with buffer containing 0.35 M NaCl, 2.5 
mM Tris (pH 7.5), and 0.02% NaN3. Fractions with gp120-antibody complexes were concentrated to 
~10 mg/ml and used for crystallization experiments. All gp120-Fab complex were screened against 
576 crystallization conditions using a Cartesian Honeybee crystallization robot. Initial crystals were 
grown by the vapor diffusion method in sitting drops at 20 °C by mixing 0.2 μl of protein complex with 
0.2 μl of reservoir solution. Crystals were manually reproduced in hanging drops by mixing 0.50 μl 
protein complex with 0.5 μl reservoir solution.  
The HT593 gp120-HJ16 complex was crystallized with a reservoir solution containing 25% 
(w/v) PEG2000, 0.2 M Li2SO4, 0.1 M Tris-HCl pH 8.5 and 5% (v/v) isopropanol and was flash frozen 
in liquid nitrogen with 15% 2R, 3R-butanediol (v/v) as a cryoprotectant. The 93TH057 coree gp120-
VRC13 complex was crystallized with a reservoir solution of 9.5% w/v PEG 8000, 15% (v/v) 
isopropanol, 0.1 M imidazole, pH 6.5 and was flash frozen in liquid nitrogen with 15% (v/v) 2R,3R-
butanediol as a cryoprotectant. The 93TH057 coree gp120-VRC16 complex was crystallized with a 
reservoir solution of 7.5% (w/v) PEG 8000, 0.1 M CHES, pH 9.5 and was flash frozen in liquid 
nitrogen with 30 % (v/v) glycerol as a cryoprotectant. The 93TH057 coree gp120-VRC18 complex 
was crystallized with a reservoir solution of 9.0% (w/v) PEG 8000, 4.5% (v/v) isopropanol, 0.1 M 
HEPES, pH 7.5 and was flash frozen in liquid nitrogen with 15% (v/v) 2R,3R-butanediol as a 
cryoprotectant. The Q23.17 coree gp120-VRC27 complex was crystallized with a reservoir solution 
of 4% (v/v) PEG 400, 1.9 M (NH4)2SO4, 0.1 M Tris-HCl, pH 8.5 and was flash frozen in liquid 
nitrogen with 10% (v/v) 2R,3R-butanediol as a cryoprotectant. The 93TH057 coree gp120-1B2530 
complex was crystallized with a reservoir solution of 8% w/v PEG 8000, 0.2 M sodium acetate and 
0.1 m sodium cacodylate, pH 6.5 and was flash frozen in liquid nitrogen with 15%(v/v) 2R,3R-
butanediol as a cryoprotectant. The YU2 coree gp120-8ANC131 complex was crystallized with a 
reservoir solution of 6% w/v PEG 3000, 0.1 M HEPES pH 7.5 and 0.2M NaCl, and was flash frozen 
in liquid nitrogen with 30% ethylene glycol as a cryoprotectant. The Q842.d12 coree gp120-
8ANC134 complex was crystallized with a reservoir solution of 2.0% (v/v) PEG 400, 2.0 M 
(NH4)2SO4 and was flash frozen in liquid nitrogen with 30% xylitol as a cryoprotectant. 
Data for all crystals were collected at a wavelength of 1.00Å at SER-CAT beamlines ID-22 
and BM-22 (Advanced Photon Source, Argonne National Laboratory). All diffraction data were 
processed with the HKL2000 suite (Otwinowski and Minor, 1997), structures were solved by 
molecular replacement using PHASER (McCoy et al., 2007), and iterative model building and 
refinement were performed in COOT (Emsley and Cowtan, 2004) and PHENIX (Adams et al., 2010), 
respectively. For HT593coree-HJ16 complex, a molecular replacement solution was obtained with 
search model from PDB ID 3JWD. For 93TH057coree complexes with VRC13, VRC16 and VRC18, 
molecular replacement solutions were obtained using PDB ID 3SE9 as a search model. For 
Q23.17coree-VRC27 complex, a molecular replacement solutions was obtained with search model 
from PDB ID 4J6R. For YU2coree-8ANC131 complex, a molecular replacement solution consisting 
of one complex per asymmetric unit was obtained with search models from PDB ID 3TGQ 
(unliganded YU2 coree) and PDB ID 3NGB (VRC01 Fab). For Q842d12coree-8ANC134 complex, a 
molecular replacement solution consisting of two complexes per asymmetric unit was obtained using 
the YU2coree-8ANC131 structure as search model. For 93TH057 coree-1B2530 complex, data were 
initially processed in P212121 space group. However, phenix.xtriage showed a multivariate Z score 
of 7.136. The data were reprocessed in P21 space group and molecular replacement solution 
consisting of two complexes per asymmetric unit was obtained using search models from PDB ID 
4LSU, with a final Z-score of 22.2 and log-likelihood gain of 1219. Running Phenix.xtriage with the 
newly processed data suggested twinning. Phenix.twin_map_utils was used to determine twin law 
(twin_law=h,-k,-l) and twin fraction (0.50), which were used throughout refinement.  
Cross validation (Rfree) test sets consisting of 5% of the data were used throughout the 
refinement processes and hydrogen atoms were included in the refinement model. Structure 
validations were performed periodically during the model building/refinement process with 
MolProbity (Davis et al., 2004). The HT593 coree-HJ16 structure was refined to a final Rfree value of 
21% with 93.2% residues in the favored region of the Ramachandran plot, and 1.1% outliers. The 
93TH057 coree-VRC13 structure was refined to a final Rfree value of 24.9% with 92.0% residues in 
the favored region of the Ramachandran plot, and 1.4% outliers. The 93TH057 coree-VRC16 
structure was refined to a final Rfree value of 20.4% with 95.8% residues in the favored region of the 
Ramachandran plot, and 0.39% outliers. The 93TH057 coree-VRC18 structure was refined to a final 
Rfree value of 20.9% with 98% residues in the favored region of the Ramachandran plot, and no 
outliers. The Q23.17coree-VRC27 structure was refined to a final Rfree value of 27.4% with 93.3% 
residues in the favored region of the Ramachandran plot, and 2.14% outliers. The 93TH057 coree-
1B2530 structure was refined to a final Rfree value of 35% with 93.04% residues in the favored region 
of the Ramachandran plot, and 19 (1.25%) outliers.YU2coree-8ANC131 structure was refined to a 
final Rfree value of 25.2% with 96.3% residues in the favored region of the Ramachandran plot, and 3 
(0.39%) outliers. The Q842d12coree-8ANC134 structure was refined to a final Rfree value of 26.4% 
with 96.2% residues in the favored region of the Ramachandran plot, and 7 (0.48%) outliers (Table 
S2). All figures containing representations of protein crystal structures were made with PyMOL 
(DeLano, 2002). gp120 and antibody interactions were analyzed with the PISA server (Krissinel and 
Henrick, 2007) (Table S6). 
 
Neutralization Fingerprints 
The neutralization fingerprint of an antibody is defined as the potency pattern with which the 
antibody neutralizes a set of viral strains. For a set of strains representing the global HIV-1 Env 
diversity, antibody neutralization fingerprints can be used as a predictor of the antibody epitopes: 
antibodies targeting similar epitopes exhibit similar fingerprints, and vice versa (Georgiev et al., 
2013). Antibody neutralization data over a set of 168 diverse HIV-1 strains (the largest set of strains 
for which data was available for all antibodies included in the analysis) was used in the analysis. For 
antibodies with multiple repeats of the neutralization experiment, the average of the repeats was 
used in the computation. Neutralization-based antibody clustering was performed as described 
previously (Georgiev et al., 2013); briefly, Spearman correlations were computed between the 
neutralization fingerprints for each pair of antibodies, effectively transforming the antibody-virus 
neutralization matrix into an antibody-antibody correlation matrix. The computed antibody-antibody 
correlations were then used to cluster the antibodies according to neutralization fingerprint similarity. 
The computation was performed using Mathematica code as published previously (Georgiev et al., 
2013). 
 
Germline Gene Usage of the VH Gene-Restricted Antibodies 
Two key features of the VH1-2- and VH1-46-restricted classes of CD4 binding site antibodies 
are the CDR H2-dominated interface and the Arg71 interaction with Asp368 of gp120. In these 
antibodies the conformation of CDR H2 is critical for interacting with the CD4 binding site loop of 
gp120 (Zhou et al., 2010). The conformation of CDR H2 in the VH1-2 and VH1-46 antibodies is in 
fact a very common conformation of this loop in antibody structures - designated the H2-10-1 
conformation as defined by North and colleagues (North et al., 2011). Since this is a common 
conformation, it might not seem to be a critical factor in germline selection. However, the identity of 
residue 71 has been noted to strongly correlate with the conformation of CDR H2 (North et al., 2011; 
Tramontano et al., 1990). Specifically, when residue 71 is Arg, CDR H2 generally adopts a very 
different conformation (H2-10-2) and the side chain of Arg71 is buried between CDR H1 and CDR 
H2. Both the H2-10-2 conformation and the buried Arg71 would be incompatible with CD4-mimetic 
binding to gp120. Why does this not happen for the VH-restricted antibodies? One possibility is that 
Pro52A may stabilize the H2-10-1 (VRC01-like) conformation of CDR H2 and this correlates with the 
Arg71 side chain being exposed rather than buried. Of 29 of the most frequently utilized human VH 
genes, only VH1-2 and VH1-46 have both Arg71 and Pro52A. Only two families of human V genes 
possessing Arg71: VH1 and VH3. However, none of the functional germline VH3 family members 
(*01 alleles) have Pro52A.  
We have examined structures of various Arg71-containing VH1- and VH3- derived antibodies 
to determine whether the side chain of Arg71 is in an exposed or buried position. Overall, VH3-
derived antibodies generally bury Arg71 between CDR H1 and CDR H2. Conversely, the VH1-2- and 
VH1-46-derived antibody structures that we have examined (including 5 non-CD4 binding site 
antibodies) all have Arg71 exposed. Antibodies derived from VH1-3, which lacks Pro52A, also have 
Arg71 exposed. In this case residue 58 (a Lys in VH1-3) may play a role in preventing this gene from 
forming CD4 mimetic antibodies. 
In addition, there are fine distinctions between CDR loop conformations (North et al., 2011). 
Strictly speaking, the CDR H2 loops of VH-restricted antibodies have H2-10-1-like conformations. 
The VRC01-gp120 complex structure (Zhou et al., 2010) has conformation H2-10-1, while the 
NIH45-46-gp120 complex structure (Diskin et al., 2011) has conformation H2-10-6, which differs by 
one peptide-flip (the amide bond plane connecting two adjacent C-alphas is flipped by 180 degrees). 
For our purposes there are two classes: H2-10-1-like (VRC01-like), or H2-10-2 (a very different 
conformation that also buries the Arg71 side chain). Some VH1-2 and VH1-46 class antibodies lack 
Pro52A - namely VRC-PG04 (with Thr52A) and 8ANC131/8ANC134 (residue 52A deleted). These 
changes presumably happened after initial selection, and it is possible that other residues changes 
may have occurred which stabilize the H2-10-1-like conformation independently of Pro52A. 
It is worth noting that VH-restricted antibodies have been isolated from 11 individuals thus 
far. It is possible that compatible but infrequently-used germline genes may not have been observed. 
Since antibody development is a stochastic process, we have restricted our analysis to the more 
frequently used VH genes – specifically, those 29 VH gene segments with a frequency >~1.1%, as 
measured by (Arnaout et al., 2011).Pro52A appears to favor the CDR H2 conformation necessary 
for CD4-mimetic binding and helps ensure that Arg71 is exposed rather than buried between CDR 
H1 and CDR H2 to promote the critical interaction with Asp368gp120. Large residues at position 58 
may be incompatible for VH-restricted antibodies due to steric clashes with V5 and Loop D. 
 
High-Throughput Sequencing 
Amplicon for 454 next-generation sequencing was prepared as described (Wu et al., 2011) 
(Zhu et al., 2012) with slight modifications as indicated. Briefly, mRNA was prepared from 10–
20 million PBMC using an Oligotex kit (Qiagen). cDNA was synthesized using Superscript II reverse 
transcriptase (Invitrogen) and oligo-dT(12–18) primers. Individual PCR reactions were performed 
with Phusion polymerase for 30 cycles. Primers had adapters for 454 next generation sequencing 
and have all been previously published. Forward primers were either specific for all VH1 (Scheid et 
al., 2011) or VH3 (Tiller et al., 2008) family genes while reverse primers were a mix of mu and 
gamma specific (Doria-Rose et al., 2014). Pyrosequencing of the PCR products was performed on a 
GSFLX sequencing instrument (Roche-454 Life Sciences, Bradford, CT, USA) on a half chip per 
reaction. The averaged raw reads are listed in Table S6. 
 
Bioinformatics Processing of 454 Data and Cross-Donor Phylogenetic Analysis 
All six 454 heavy chain sets were filtered for read length keeping only those sequences with 
a minimum of 300 nucleotides. The remaining sequences from each data set were then submitted to 
the IMGT High-Vquest server (http://www.imgt.org/IMGTindex/IMGTHighV-QUEST.html) for 
processing and germline gene assignment. Each processed 454 data set was filtered using four VH 
family germline genes: 1) VH1-2; 2) VH1-46; 3) VH1-69; and 4) VH3-23. The resulting data sets 
were then analyzed using cross-donor phylogenetic analysis (Zhu et al., 2011).  
The cross-donor phylogenetic analysis used here is similar to one we reported previously 
(Zhu et al., 2011). The major objective of cross-donor phylogenetic analysis is to bracket all 
phylogenetically similar sequences on a Neighbor-Joining (NJ) tree using known neutralizing 
antibody sequences. For the analysis here, we used pairs of neutralizing antibody sequences 
discovered from each of the six heavy chain 454 data sets (for a total of twelve neutralizing antibody 
sequences). The variable domain sequences of the following twelve neutralizing antibodies were 
used: 1) VRC01 (donor 45); 2) VRC03 (donor 45); 3) gVRCdC38H3 (donor C38); 4)VRC18.02 
(donorC38); 5) 1B2530 (donor RU01); 6) 1NC3 (donor RU01); 7) 8ANC131 (donor RU08); 8) 
8ANC134 (donor RU08); 9) VRC13.01 (donor 44); 10) VRC13.02 (donor 44); 11) VRC16.01 (donor 
C38); and 12) VRC16.02 (donor C38). 
The method was carried out in an iterative fashion and began by randomly shuffling all the 
sequences in a data set. Shuffling of the sequences removed any potential bias in the ordering of 
the sequences and improved convergence (Zhu et al., 2013). After sequence shuffling, the data set 
were split into FASTA files each containing up to 5000 sequences. All the neutralizing antibody 
sequences along with a germline gene sequence were added to each FASTA file. The germline 
gene sequence was chosen based on the VH family germline gene filter and was used as the 
outgroup in the NJ tree. A multiple sequence alignment for each FASTA file was generated using 
CLUSTAL0 (Larkin et al., 2007) with default settings. Each multiple sequence alignment was then 
converted into a distance matrix using the dnadist program (with default settings). From this, a NJ 
tree was constructed using the neighbor program (with default settings). Both dnadist and 
neighbor are part of the PHYLIP package v3.69 and can be downloaded from: 
(http://evolution.genetics.washington.edu/phylip.html). 
Donor sequences were extracted from each NJ tree using a pair of neutralizing antibody 
sequences with matching VH genes as references. All donor sequences that were one node above 
the minimal-spanning tree containing the pair of neutralizing sequences were extracted from the NJ 
tree. The extracted sequences were then split into FASTA files containing no more than 5000 
sequences and the above process repeated five times: 1) random shuffling of sequences; 2) addition 
of twelve neutralizing antibody sequences (including germline sequence); 3) alignment using 
CLUSTAL0; 4) conversion to a distance matrix using dnadist; 5) construction of a NJ tree using 
neighbor; and 6) extracting sequences one node above the minimal-spanning tree containing the 
pair of neutralizing antibody sequences. Sequences from each of the 454 data sets were pooled and 
sequence identities were computed between extracted donor sequences and the reference 
neutralizing antibody sequences. All sequences above 80% sequence identity were considered 
cross-donor relatives and the total number should appear off diagonal in Figure 4B.  
 
Structure Modelling on the Mature Closed HIV-1 Viral Spike 
 The BG505.664 SOSIP crystal structure (PDB ID: 4TVP) was used to analyze the 
recognition of CD4-binding site by antibodies in a trimer context. First the trimer coordinates was 
transformed so that the trimer axis is on the z-axis and the center of the CD4-bindig site on outer 
domain of one protomer gp120 is on the x-axis. The outer domains of gp120 proteins of CD4-binding 
site antibody complexes were then superimposed to the x-axis-aligned protomer by aligning residues 
252-392, 412-422, 437-476. The centers for the variable and constant domains of antibody Fab were 
defined by the averaged coordinates of Cα-atoms of the 2 pairs of conserved cystines in each 
domain, respectively. The long axis of antibody Fab was represent by the line connecting the centers 
(Figure S3). Approaching mode to the targeted gp120 protomer for each antibody was represented 
by the vector from the center of CD4-binding site on outer domain to the center of Fv domain of each 
antibody (Figure 2B). On the viral spike, the mode of recognition for CD4-binding site antibodies was 
quantified with two angles, the latitudinal angle which explores the freedom between the viral 
membrane and the host cell membrane along the trimer axis, and the longitudinal angle which 
explores the freedom between gp120/gp41 protomers. The latitudinal angle was defined as the 
angle formed by the trimer axis (z-axis) and the projection of antibody vector on the y-z plane; and 
the longitudinal angle was defined as the angle formed by the protomer axis (x-axis) and the 
projection of antibody vector on the x-y plane.  
 
Calculation of Positional Difference between gp120-Bound Antibodies 
To obtain a common reference frame for comparison, all antibody-gp120 complexes to be 
analyzed were first superposed over the outer domain of gp120 (residue ranges: 252-392, 412-422, 
437-476). The calculations of rotation angles and Cα-root mean square deviation (rmsd) between 
gp120-bound antibodies (or their heavy or light chains or structural components) were then carried 
out with the gp120-aligned structures. For comparison of heavy chains positions, the frame work 
regions (residues 1-22, 36-49, 76-82 and 103-114) were superimposed. For comparison of CDR L3s 
positions, the light chain residues 89-97 were superimposed. The superposition procedures were 
performed with the Superpose Molecules module in CCP4 (Collaborative Computational Project, 
1994). The CHI angle of the CCP4 output was taken as the rotation angle between a compared pair.  
 
Determination of the CD4 Supersite by Antibody Breadth  
Average buried surface area (BSA) on gp120 was calculated for residues with BSA > 1Å2 for 
the 16 gp120-antibody complexes, and the corresponding antibody neutralization potencies were 
averaged for each of those residues based on data from neutralization assays. Spearman 
correlation between BSA on gp120 and antibody potencies was calculated for BSA cutoffs = 0 to 85 
Å2 and potency logIC50 cutoffs = 0.60 to 1.62 (µg/ml). 
 
Analysis of Antibody Paratope Chemistry  
Representative structures of gp120-antibody complexes, including 11 from 2 VH gene-
restricted classes (VH1-2 and VH1-46) and 4 CDR H3-dominated classes, were used in the 
analysis. Residues from each antibody were defined as part of the paratope if greater than 30% of 
residue surface area was buried in the interaction with gp120 in the relevant complex crystal 
structure. Buried surface area was calculated with SurfV (Nicholls et al., 1991). Paratope residues 
engaged in hydrogen-bonded or salt bridge interactions with gp120 were defined using hbplus 
(McDonald and Thornton, 1994). 
 
Definition of Protein Atom Types 
The atoms in twenty natural amino acids are divided into 30 protein atom types and are 
classified into 5 atom type groups (Table S7). 
 gp120 Proteoliposomes 
A proteoliposome platform (Lingwood et al., 2012) was used to display multivalent gp120 for 
BCR activation. One gram of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and 1,2-dioleoyl-sn-
glycero-3-[(N-(5-amino-1-carboxypentyl)iminodiacetic acid) succinyl] (nickel salt) [DGS-NTA(Ni )] 
(Avanti Polar Lipids Inc.) were mixed a 1:1 molar ratio was evaporated under a stream of nitrogen for 
1 hr. The dry lipid film was then rehydrated in 1000 ml of liposome buffer [50 mM HEPES, 150 mM 
NaCl, pH 7.25 (HBS)] and shaken for 40 min, all the time being heated above the Tm of the lipid 
mixture. The resulting homogeneous suspension was subjected to ten freeze-thaw cycles and then 
extruded 21 times through a 100-nm pore polycarbonate membrane to produce uniform 100 nm 
liposomes (Avanti mini-extruder, Avanti Polar Lipids Inc.). An AviHis-tagged version of the YU2 
gp120 core(Wu et al., 1996) was purified as wild type or mutant for recognition of its CD4 supersite 
(A281R, G366R, D368R, P369R) on a 17b affinity column as described(Kwon et al., 2012). One 
hundred twenty five micrograms of YU2 (wild type or mutant) was added to 0.5 mg of liposome 
suspension and left rocking at room temperature in a volume of 260 µl (HBS) for 45 min. The sample 
was then adjusted to 15% iodixanol (in 1.25 mL HBS) and overlaid with 1.75 mL, 0.5 mL and 0.5 mL 
of 10%, 2.5% and 0% iodixanol in HBS, respectively. Samples were then centrifuged for 200000g in 
a TH660 rotor (Sorvall) for 2 hr. The proteoliposome fraction, which concentrated at the 2.5%-0% 
iodixanol interface, was collected and dialyzed overnight (Slide-A-Lyzer Dialysis Cassette, 10000 
MWCO, Cat# 66380, Thermo Scientific) to remove density gradient material. Following dialysis, 
proteoliposomes were pelleted (200000g, 2hr, TH660 rotor), resuspended in HBS and measured by 
the Pierce BCA protein assay (Cat# 23227, Thermo Scientific). WT and mutant YU2 showed equal 
liposomal loading as measured by protein yield. 
 
BCR Activation Assay 
Mature and germline (gHgL) BCRs for VRC01 and VRC13 were stably expressed by 
lentiviral transfection (FEEKW vector (Luo et al., 2009)) of light chain and IgM heavy chain into a 
surface IgM negative clone of Ramos B lymphocytes (Lingwood et al., 2012). BCR positive cells 
[defined as staining positive for both light chain (mouse PE-anti-human lambda chain, Cat# 555797, 
BD Biosciences) and IgM (APC-anti-human IgM, Cat# 314510, BioLegend)] were then sorted by flow 
cytometry (BD FACSAria, BD Biosciences) and amplified. Cells were evaluated for triggering when 
BCR reached >85% expression. For signaling, 1×106 cells expressing mature or germline BCR were 
exposed to 2.5 µg/ml and 5 µg/ml YU2 proteoliposome, respectively. The kinetics of calcium flux in 
response to BCR stimulation was measured by flow cytometry as the ratio of the Ca2+ 
bound/unbound states of the dye Fura Red (Novak and Rabinovitch, 1994). Ratiometric measures 
for individual cells were averaged, smoothened (Kinetic analysis, Flow Jo software) and 
standardized to total Ca2+ flux as measured by exposure of cells to 10 µg/ml ionomycin. Comparable 
surface expression between all four BCRs was confirmed by equivalent Ca2+ flux following exposure 
to mouse 5 µg/ml anti-human IgM F(ab’)2 (Cat# 9023-01, SouthernBiotech). 
  
Table S2. Crystallographic Data Collection and Refinement Statistics, Related to Figure 1 
 
Complex (antibody-gp120) VRC13-93TH057 VRC16-93TH057 VRC18-93TH057 VRC27-Q32.17 
PDB ID 4YDJ 4YDK 4YDL 4YDI 
Data collection     
Space group P21212 C2 P21 C222 
Cell dimensions       
a, b, c (Å) 293.8, 67.1, 93.6 125.8, 109.7, 100.1 66.3 213.1 68.2 141.7, 172.3, 91.8 
α, β, γ  (°)  90.0, 90.0, 90.0 90.0, 126.3, 90.0 90.0 90.2 90.0 90.0, 90.0, 90.0 
Resolution (Å) 50.00-2.31 
(2.34-2.30) 
50.00 -2.05 
(2.09-2.05) 
50.00-1.80 
(1.83-1.80) 
50.00-3.45 
(3.57-3.45) 
R sym or Rmerge 0.141(0.833) 0.072(0.462) 0.063(0.721) 0.143(0.348) 
I/σI 13.4(2.0) 22.6(2.2) 17.6(2.0) 10.8(2.1) 
Completeness (%) 99.3(95.2) 98.5(88.5) 99.0(98.9) 88.6(58.1) 
Redundancy 5.0(3.2) 3.7(3.1) 3.5(3.2) 5.5(3.4) 
     
Refinement     
Resolution (Å) 2.30 2.05 1.80 3.45 
No. reflections 81465 67455 175574 13713 
Rwork/  R free 22.3/25.0 16.6/20.6 17.4/20.7 22.2/27.6 
No. atoms     
    Protein 11354 6071 12050 5959 
    Ligand/ion 367 280 353 215 
    Water 375 462 1402 25 
B-factors     
    Protein 90.3 52.2 43.9 108.8 
    Ligand/ion 88.5 83.4 66.7 112.50 
    Water 63.7 49.8 49.3 70.7 
R.m.s deviations     
    Bond lengths (Å)  0.003 0.003 0.007 0.004 
    Bond angles (º) 0.731 0.754 1.030 1.021 
Ramachandran statistics     
   Favored (%) 94.1 96.8 98.5 94.5 
   Outliers (%) 0.2 0.13 0 0.54 
 
Complex (antibody-gp120) 8ANC131-YU2  8ANC134 –Q842.d12 1B2530-93TH057  HJ16-HT593.1 
PDB ID 4RWY 4RX4 4YFL 4YE4 
Data collection     
Space group P212121 H3 P21 I222 
Cell dimensions       
a, b, c (Å) 66.2, 67.1, 214.1  220.4, 220.4, 118.5 67.0, 57.3, 254.7 87.7, 99.0, 180.4 
α, β, γ  (°)  90.0, 90.0, 90.0 90.0, 90.0, 120.0 90.0, 90.11, 90.0 90.0, 90.0, 90.0 
Resolution (Å) 50.00-2.39 (2.45-2.39, 
2.16-2.12) 
50.00-3.4  
(3.58 -3.45) 
50.00-3.43  
(3.49-3.43) 
50.00-2.71 
(2.81-2.71) 
R sym or Rmerge 0.093 (0.351, 0.477) 0.103 (0.775) 0.129 (0.488) 0.085(0.444) 
I/σI 12.36 (3.31, 1.74) 14.36 (2.34) 6.45 (2.21) 12.41 (2.32) 
Completeness (%) 72.8 (53.8, 17.3) 99.6 (100) 92.1 (93.5) 94.5 (67.8) 
Redundancy 6.2 (4.6, 2.8) 4.1 (4.1) 2.4 (2.1) 4.6 (2.5) 
     
Refinement     
Resolution (Å) 28.84-2.13 26.90-3.45 28.78 -3.43 41.9-2.71 
No. reflections 43292 28017 24702 20510 
Rwork/  R free 21.5/24.6 20.7/24.6 27.0/32.4 21.7/26.1 
No. atoms     
    Protein 6149 11740 12254 6043 
    Ligand/ion 117 215 120 126 
    Water 228 0 0 37 
B-factors     
    Protein 58.8 106.20 209.0 69.7 
    Ligand/ion 73.3 121.80 212.2 103 
    Water 47.8 NA 0 47 
R.m.s deviations     
    Bond lengths (Å)  0.003 0.009 0.010 0.004 
    Bond angles (º) 0.783 1.36 1.853 0.82 
Ramachandran statistics     
   Favored (%) 96.3 95.9 90 93.2 
   Outliers (%) 0.39 0.88 1.1 1.1 
Values in parenthesis denote highest resolution shell.  
 
Table S3A. Basic Information of Monoclonal CD4-Binding Site Antibodies Isolated from Human 
Donor Samples, Related to Figure 2 
 
Type 
(structural 
mode of HIV-1 
recognition 
used by each 
antibody 
class) 
Class 
(Clonal 
families with 
related 
ontogenies in 
separate 
donors) 
Clonal lineage 
(Clonal related 
antibodies 
which derive 
from the same 
naïve 
rearranged B 
cell) 
Donor 
(Subject from 
whom the 
clonal family 
was isolated) 
Representative 
monoclonal  
(Best characterized 
monoclonal antibody 
of each clonal family) 
Isolation 
methoda 
VH 
gene 
CDR H3 
lengtha, b 
(amino acids) 
Vλ/κ 
genea 
CDR L3 
lengtha, b 
(amino acids) 
Breadth on 
172-virus 
panela 
(Defined as 
IC50<50 
μg/ml)  
CDR H3 
dominated 
HJ16 class HJ16 242315 HJ16* EBV 3-30 18 κ 4-1 8 30% 
VRC13 class VRC13 44 VRC13* RSC3-probe 1-69 21 λ 2-14 6 82% 
VRC16 class VRC16 C38 VRC16* RSC3-probe 3-23 20 κ 1-39 9 57% 
CH103 class CH103 CHAVI 505 CH103*, CH104, CH106 RSC3-probe 4-59 13 λ 3-1 10 56% 
VH gene 
restricted 
VRC01 class 
[VH1-2-
derived] 
VRC01 45 
VRC01*, VRC02, 
VRC03, VRC06, 
VRC07, VRC08, 
NIH45-46 
RSC3-probe 1-2 12 κ 3-20 5 90% 
VRC23 127/C VRC23* RSC3-probe 1-2 12 κ 3-15 5 65% 
VRC18 C38 VRC18* RSC3-probe 1-2 10 κ 3-20 5 81% 
VRC-CH31 CHAVI0219 
VRC-CH30, VRC-
CH31*, VRC-CH32, 
VRC-CH33, VRC-
CH34 
RSC3-probe 1-2 13 κ 1-33 5 81% 
VRC-PG20 IAVI23 
VRC-PG19, VRC-
PG19b, VRC-PG20*, 
VRC-PG20b 
RSC3-probe 1-2 13 λ 2-14 5 78% 
12A21 IAVI57 12A21*, 12A12, 12A30 2CC-probe 1-2 13 κ 1-33 5 85% 
VRC-PG04 IAVI74 VRC-PG04*, VRC-PG04b RSC3-probe 1-2 14 κ 3-20 5 79% 
VRC27 Z258 VRC27* RSC3-probe 1-2 14 κ 1-33 5 78% 
3BNC117 RU3 3BNC117*, 3BNC60, 3BNC62 2CC-probe 1-2 10 κ 1-33 5 84% 
8ANC131 
class 
[VH1-46-
derived] 
1B2530 RU1 1B2530*, 1NC3, 1NC7 2CC-probe 1-46 16 λ 1-47 11 43% 
8ANC131 RU8 8ANC131*, 8ANC134*, 8ANC37 2CC-probe 1-46 16 κ 3-20 9 79% 
*Structural analysis of this monoclonal antibody is described in this paper. 
aPertains to monoclonal antibodies marked with asterisks. 
bKabat definition, in which CDR H3 is 2 amino acids shorter than the IMGT definition. 
 
 
Table S3B. Characteristic Features of Antibody Types Targeting the CD4 Supersite, Related to 
Figure 2 
 
 CDR H3-dominated VH-gene-restricted 
Observed classes CH103, HJ16, VRC13, VRC16 VRC01-class (VH1-2) 8ANC131-class (VH1-46) 
Overall 
All antibodies have the same 
latitudinal binding orientation 
as CD4, but freedom in 
longitudinal dimension 
All antibodies have 
essentially  the same 
binding orientation 
All antibodies have 
essentially  the same 
binding orientation, but 
more freedom than VH1-2 
Heavy chain CDR H3 > 50% contact surface 
CDR H2 > 50% contact 
surface 
CDR H2 > 50% contact 
surface 
Light chain Diverse CDR L2 and L3 interaction modes. 
5-amino-acid CDR L3 
with third position 
hydrophobic and fourth 
position E/Q 
CDR L3 length not 
constrained to 5 amino 
acids. 
  
 
Table S4. Contribution of Antibody CDRs to HIV-1 gp120 Binding, Related to Figure 2 
 
Antibody 
Light chain  Heavy chain 
paratope (Å2)  paratope (Å2) 
CDRL1 CDRL2 CDRL3 Total  CDRH1 CDRH2 CDRH3 Total 
CH103 72.1 116.6 74.42 362.1  30.1 77.3 328.9 461.8 
HJ16 146.7 0 215.9 362.6  31.9 120.5 482.1 634.5 
VRC13 7.01 14.8 0 21.8  114.9 23.1 574.0 966.1 
VRC16 106.8 40.8 110.01 297.0  0 191.0 674.1 944.9 
          
VRC01 113.4 0 113.4 308.6  2.2 607.2 122.5 883.4 
VRC04 58.7 0 131.2 216.8  19.6 431.6 181.0 749.9 
VRC18 54.7 0 121.1 220.0  65.0 637.8 94.7 920.0 
VRC20 57.1 0 149.2 206.3  34.7 751.6 137.6 1111.2 
VRC23 24.6 0 182.0 342.8  10.5 567.6 135.1 876.3 
VRC27 13.3 0 133.2 215.4  24.8 569.3 158.1 991.6 
12A21 120.0 0 84.4 245.3  4.4 698.6 229.7 1131.3 
3NBC117 56.6 0 97.6 269.2  53.4 484.8 107.6 802.4 
CH31 118.4 0 168.6 395.8  39.8 425.6 100.5 618.0 
          
1B2530 1.6 0 216.8 245.2  0 553.1 121.5 820.8 
8ANC131 19.8 11.2 158.2 212.9  24.7 464.2 155.2 992.8 
8ANC134 13.6 0 0 180.0  25.6 448.6 181.8 1044.0 
 
  
 
Table S5. 454 Pyrosequencing of B Cell Transcripts by Donor and by VH-Gene Family, Related to 
Figure 4 
 
Donor  45
a  C38
b  RU01
c  RU08
 c  44
 c  C38
 c 
Number Raw 
Reads  696,971  290,744  345,080  315,711  478,517  395,545 
Number Reads 
> 300bp  696,971  266,975  325,054  296,274  457,961  368,902 
Number Reads 
(VH1-2)  175,137  77,797  17,468  16,108  41,384  0 
Number Reads 
(VH1-46)  41,535  32,959  18,972  4,053  43,793  0 
Number Reads 
(VH1-69)  220,497  56,986  198,536  187,177  213,058  265 
Number Reads 
(VH3-23)  0  0  0  0  0  59,236 
 
a. Donor 45 data was from a previous deposit at the National Center for Biotechnology Information Short Reads Archives under 
accession code SRP052625 (Wu et al., 2015). The heavy chain data from year 2008 time point was used in this study. 
b. Donor 38 data (for VRC18.02) was from a previous deposit at the National Center for Biotechnology Information Short Reads 
Archives under accession code SRP026397 (Zhu et al., 2013). 
c. NGS data for donors RU01, RU08, 44 and C38 (for VRC16.01) were obtained in this study and deposit at the National Center for 
Biotechnology Information Short Reads Archives under accession code SRP055520. 
  
 
Table S7. The Atom Types of 20 Natural Amino Acids, Related to Figure 7 
 
Atom 
type 
Group * 
Polar 
atom 
Group 
Protein 
Atom 
Type 
Atom 
Radius 
(Å) 
Description Number 
B N NH1 1.65 Backbone NH 1 
B  CB 1.76 Backbone C 2 B  CH1E 1.87 Backbone CA (exclude Gly) 3 B O OB 1.40 Backbone O 4 
C  CH2G 1.87 Gly CA 13 C  CH0 1.76 Arg CZ, Asn CG, Asp CG, Gln CD, Glu CD 5 C  CH1S 1.87 Sidechain CH1: Ile CB  Leu CG, Thr CB, Val CB 6 C  CH2P 1.87 Pro CB, CG and CD 14 C  CH2E 1.87 Tetrahedral CH2 (except CH2P and CH2G) All CB 7 C  CH3E 1.87 Tetrahedral CH3 8 A  CR1E 1.76 Aromatic CH (except CR1W, CRHH, CR1H) 9 A  CF 1.76 Phe CG 21 A  CY2 1.76 Tyr CZ 19 A  CY 1.76 Tyr CG 23 A  CR1W 1.76 Trp CZ2 and CH2 18 A  CW 1.76 Trp CD2 and CE2 24 A  C5W 1.76 Trp CG 30 C  CRHH 1.76 His CE1 25 C  CR1H 1.76 His CD2 27 C  C5 1.76 His CG 28 S  SC 1.85 Cys S 20 S  SM 1.85 Met S 22 P OH1 OH1 1.40 Alcohol OH (Ser OG, Thr OG1 and Tyr OH) 10 
P OCS OS 1.40 Sidechain O. Asn OD1 and Gln OE1 12 
P OCS OC 1.40 Carboxyl O (Asp OD1, OD2 and Glu OE1, OE2) 11 
P  ProN 1.65 Pro N 29 P NS NH1S 1.65 Sidechain NH: Arg NE, His ND1, NE2 and Trp NE1 15 
P NS NH2 1.65 Asn ND2 and Gln NE2 17 
P NS NC2 1.65 Arg NH1 and NH2 16 
P NS NH3 1.50 Lys NZ 26 
 
*: First column from left: B is for backbone atom types; C is for aliphatic carbon atom types; A is for aromatic carbon atom types; S is for sulfur atom 
types; P is for polar atom types. Second column from left: The polar atom groups. N denotes backbone N; O denotes backbone O; OH1 denotes OH1 
atom type; OCS denotes OS and OC atom types; NS denotes NH1S, NH2, NC2 and NH3 atom types. The third and fourth columns show the protein 
atom types and van der Waals radii respectively. The description of the protein atom types are shown in the fifth column. 
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